Comparative Pharmacology
Head-to-head clinical analysis: SULMEPRIM versus SULTEN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULMEPRIM versus SULTEN 10.
SULMEPRIM vs SULTEN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulmeprim is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits sequential steps in bacterial folate synthesis, leading to bactericidal activity.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Adults: 800 mg sulfamethoxazole/160 mg trimethoprim (one double-strength tablet) orally every 12 hours for 10-14 days. For severe infections or pneumonia, intravenous dose: 15-20 mg/kg/day (based on trimethoprim component) divided every 6-8 hours.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
None Documented
None Documented
Terminal elimination half-life is 10-12 hours in patients with normal renal function, allowing twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life extends to >20 hours, requiring dose adjustment.
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Renal excretion of unchanged drug accounts for 70% of elimination; 20% is metabolized in the liver to inactive metabolites (glucuronide conjugates) and excreted in urine; 10% is eliminated in feces via biliary excretion.
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic